e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Occupational exposures and disease II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
MCS patients have decreased FeNO
L. Barbinova, X. Baur, M. Oldenburg (Hamburg, Germany)
Source:
Annual Congress 2009 - Occupational exposures and disease II
Session:
Occupational exposures and disease II
Session type:
Thematic Poster Session
Number:
1068
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Barbinova, X. Baur, M. Oldenburg (Hamburg, Germany). MCS patients have decreased FeNO. Eur Respir J 2009; 34: Suppl. 53, 1068
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
Related content which might interest you:
FeNO is not affected by spirometry, IOS or walking in healthy subjects or well controlled asthma patients
Source: Virtual Congress 2020 – Clinical characteristics and diagnostic tools for phenotyping asthma and COPD
Year: 2020
Exhaled NO (FeNO) levels in patients with exacerbation of COPD and/or bronchiectasis
Source: International Congress 2018 – Biomarkers for evaluating COPD
Year: 2018
The relationship between fractional exhaled nitric oxide and asthma symptom scores in patients on mepolizumab
Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification
Year: 2019
Raised FeNO is associated with lower FEV1 and FEV1/FVC in children with asthma
Source: International Congress 2019 – Paediatric asthma: risk factors, biomarkers and the basics
Year: 2019
FeNO
Source: Annual Congress 2009 - PG11 Paediatric lung function testing - an interactive course
Year: 2009
8-Isoprostane and FeNO levels in IPF and sarcoidosis patients (Preliminary results)
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
Exhaled nitric oxide (FeNO), sputum analysis and asthma control score in children with mild to moderate asthma
Source: Annual Congress 2008 - Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children
Year: 2008
Ensifentrine added on to tiotropium significantly improves lung function, symptoms and QoL in symptomatic COPD patients regardless of baseline reversibility
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020
Diagnostic value of FeNO in COPD and asthma - COPD overlap syndrome
Source: International Congress 2016 – Assessing lower airway inflammation with different tools
Year: 2016
The correlation between the Borg score and VAS and lung function parameters in patients with asthma and COPD
Source: Annual Congress 2010 - New diagnostic approaches in respiratory function
Year: 2010
Isocyanate-induced increase of exhaled NO (FeNO)
Source: Eur Respir J 2006; 28: Suppl. 50, 619s
Year: 2006
The relationship between symptom scores and medication adherence in stable COPD patients
Source: International Congress 2017 – COPD management
Year: 2017
FeNO (fractional exhaled nitric oxide) measurements in pregnant asthmatic women. The long-term, intra-subject variability of FeNO in controlled asthma
Source: Annual Congress 2012 - Exhaled biomarkers in airway diseases
Year: 2012
Regarding the role of
F
ENO
in predicting failure after ICS reduction in mild-to-moderate asthma patients
Source: Eur Respir J, 56 (2) 2002375; 10.1183/13993003.02375-2020
Year: 2020
Correlations between SGRQ and other clinical and functional parameters in COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 809s
Year: 2006
Factors associated with high levels of exhaled NO in children using asthma medication
Source: Annual Congress 2011 - Inflammation and genes in childhood asthma
Year: 2011
FeNO in relation to asthma control in steroid treated asthmatics
Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement
Year: 2008
Do changes in spirometric indices and FeNO predict asthma outcomes in children? An individual patient data analysis using results from seven FeNO trials
Source: International Congress 2018 – Primary ciliary dyskinesia and lung function tests in respiratory morbidities
Year: 2018
Low hematocrit as predictor of exacerbation frequency in COPD patients
Source: Annual Congress 2010 - Exacerbations and COPD and rehabilitation
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept